Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SilkByPass

Financiado

Cerrado

Develop simple tissue regeneration technologies for the benefits of humanity by...

Develop simple tissue regeneration technologies for the benefits of humanity by leveraging the biomimetic properties and the mechanical advantages of a new silk manufacturing nanotechnology. Silk Biomaterials is a nanotechnology platform company. Its goal is to revolutionize the €85bn global tissue engineering market by leveraging the biomimetic properties and the mechanical advantages of silk. SilkByPass, a device de... ver más

31/12/2015

SILK BIOMATERIALS

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

SILK BIOMATERIALS SRL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2015-12-31

NMP-25-2015-1: Accelerating the uptake of nanotech...

I+D

Cerrada hace 9 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

SILK BIOMATERIALS

50.00K€ | Lider

ROCA SANITARIO

665.30K€ | Participante

Proyectos interesantes

DIALYBRID

Medical Technol...

Materials Scien...

71K€ Cerrado

BIOSCENT

Medical Technol...

Nanotechnology

8M€ Cerrado

FJC2020-045920-I

Medical Technol...

Nanotechnology

53K€ Cerrado

HUMAN TEXTILES

Medical Technol...

Materials Scien...

2M€ Cerrado

SEEVIX Phase-1

Medical Technol...

Materials Scien...

71K€ Cerrado

MAT2012-38412-C02-01

Medical Technol...

Materials Scien...

47K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 6 meses Fecha Inicio: 2015-06-15
Fecha Fin: 2015-12-31

Líder del proyecto

SILK BIOMATERIALS SRL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Silk Biomaterials is a nanotechnology platform company. Its goal is to revolutionize the €85bn global tissue engineering market by leveraging the biomimetic properties and the mechanical advantages of silk. SilkByPass, a device designed for the regeneration of small blood vessels, will be the first product developed by Silk Biomaterials. About 560k/year coronary artery bypass graft surgeries (CABG) are performed in OECD countries. The current golden standard for CABG is autograft (mainly saphenous vein, umbilical vein and mammary artery) and very often more than one graft is required for each procedure. However, autografts are not always available and present several drawbacks: so, there is a global urgent need for man-made grafts. Very few synthetic grafts are on the market and, due to their very poor results, they are used only when autografts previously failed. There is also a need for man-made solutions for peripheral blood vessels, like saphenous veins and carotids. For those vessels there are no autografts available and small calibre synthetic grafts fail in restoring the bloodstream. Our innovative nanotechnology stimulates faster natural human tissue regeneration, with no rejection risks or use of drugs. In addition to that, it is cheaper than other synthetic grafts, allows for easy surgery and doesn’t produce any dangerous degradation product in the patient’s body. Key opinion leaders, clinicians, venture capitalists and medical device companies have already recognized its commercial potential, which is estimated to be around €3.9bn annually in OECD countries. The feasibility assessment to be undertaken in Phase 1 will help Silk Biomaterials further de-risk its technological/commercial viability and plan for a series of activities requiring Phase 2 funding (i.e.: clinical trials, reimbursement negotiations, distribution and licensing agreements, etc.) that will improve the investment readiness of our company and strengthen its long term sustainability.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores